Steve founded MVM in 1997. Prior to setting up MVM, he was responsible for healthcare investments at Saunders, Karp & Megrue. He was also involved in founding several US biotechnology companies and was the first investor in and acting CEO of UpToDate, Inc.

Steve previously worked as an Investigator of the Howard Hughes Medical Institute at Yale and was an Associate Physician at Brigham and Women’s Hospital. He has published extensively on the molecular genetics of human disease. Steve practiced medicine at the John Radcliffe, Churchill, Guys, St. Thomas’s, and Hammersmith Hospitals and the Institute of Neurology, Queen Square before taking up research at Oxford University. He holds a BA in Natural Sciences from Cambridge and an DM from Oxford.

Steve is a member of the board of Ossio, eZono AG, Vital Connect, Inc., and AccuVein, Inc. He was previously a director of Ambio, Inc., Beacon Endoscopic Ltd, BioVex Group, Inc., Cara Therapeutics, Inc., Cheetah Medical Inc., Clavis AS., Gendaq Ltd, Momenta Pharmaceuticals, Inc., Pulmagen Therapeutics Ltd., Sangamo Biosciences, Inc., UpToDate, Inc., Vascular Pathways, Inc., Xention Ltd., Patient Connect Ltd and Zipline Medical, Inc

Latest news

OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023

OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]

MVM invests in Neurolens
September 12, 2022

Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing. The financing was led by […]

MDxHealth acquires Oncotype DX GPS test
August 2, 2022

MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an […]

Nalu announces new CEO
July 14, 2022

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today […]

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]